These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3262087)

  • 1. Development of a simple radioimmunoassay for human C3a.
    Lamche HR; Paul E; Schlag G; Redl H; Hammerschmidt DE
    Inflammation; 1988 Jun; 12(3):265-76. PubMed ID: 3262087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiography and complement activation. Evidence for generation of C3a anaphylatoxin by intravascular contrast agents.
    Westaby S; Dawson P; Turner MW; Pridie RB
    Cardiovasc Res; 1985 Feb; 19(2):85-8. PubMed ID: 3872180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement activation produced by biomaterials.
    Chenoweth DE
    Artif Organs; 1988 Dec; 12(6):508-10. PubMed ID: 3265053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Demonstration of anaphylatoxins C3a, C4a and C5a in the scales of psoriasis and inflammatory pustular dermatoses.
    Takematsu H; Ohkohchi K; Tagami H
    Br J Dermatol; 1986 Jan; 114(1):1-6. PubMed ID: 3484631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A modified competitive inhibition radioimmunoassay for the detection of C3a. Use of 125I-C3 instead of 125I-C3a.
    Hack CE; Paardekooper J; Eerenberg AJ; Navis GO; Nijsten MW; Thijs LG; Nuijens JH
    J Immunol Methods; 1988 Apr; 108(1-2):77-84. PubMed ID: 3258341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C3, C5 components and C3a, C4a, and C5a fragments of the complement system.
    Janatova J
    Methods Enzymol; 1988; 162():579-625. PubMed ID: 3265757
    [No Abstract]   [Full Text] [Related]  

  • 7. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis.
    Hack CE; Nuijens JH; Felt-Bersma RJ; Schreuder WO; Eerenberg-Belmer AJ; Paardekooper J; Bronsveld W; Thijs LG
    Am J Med; 1989 Jan; 86(1):20-6. PubMed ID: 2783358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anaphylatoxin levels in human aqueous humor.
    Mondino BJ; Sumner H
    Invest Ophthalmol Vis Sci; 1986 Aug; 27(8):1288-92. PubMed ID: 3488296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioimmunoassay for anaphylatoxins: a sensitive method for determining complement activation products in biological fluids.
    Wagner JL; Hugli TE
    Anal Biochem; 1984 Jan; 136(1):75-88. PubMed ID: 6711816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitation of the anaphylatoxin C3a in the presence of C3 by a novel sandwich ELISA using monoclonal antibody to a C3a neoepitope.
    Zilow G; Naser W; Rutz R; Burger R
    J Immunol Methods; 1989 Jul; 121(2):261-8. PubMed ID: 2503562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Atopic dermatitis. II. The status of complement proteins and the pathogenetic role of anaphylatoxins C4a, C3a and C5a].
    Sergeev IuV; Reznikov IuP; Lobanova EV; Pimenova NS
    Vestn Dermatol Venerol; 1989; (4):4-7. PubMed ID: 2788339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of human C3a, C4a, and C5a anaphylatoxins by protein A of Staphylococcus aureus and immobilized protein A reagents used in serotherapy of cancer.
    Langone JJ; Das C; Bennett D; Terman DS
    J Immunol; 1984 Aug; 133(2):1057-63. PubMed ID: 6610702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simplified assay for the detection of C3a in human plasma employing a monoclonal antibody raised against denatured C3.
    Nilsson B; Svensson KE; Inganäs M; Nilsson UR
    J Immunol Methods; 1988 Mar; 107(2):281-7. PubMed ID: 3257998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of anaphylatoxin concentrations in suction blisters in patients with psoriasis.
    Ohkohchi K; Takematsu H; Tagami H
    J Invest Dermatol; 1986 Jul; 87(1):65-7. PubMed ID: 3487596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement split products and the pathogenesis of SLE.
    Abramson SB; Weissmann G
    Hosp Pract (Off Ed); 1988 Dec; 23(12):45-56. PubMed ID: 3142905
    [No Abstract]   [Full Text] [Related]  

  • 16. Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis.
    Hopkins P; Belmont HM; Buyon J; Philips M; Weissmann G; Abramson SB
    Arthritis Rheum; 1988 May; 31(5):632-41. PubMed ID: 3259882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease.
    Belmont HM; Hopkins P; Edelson HS; Kaplan HB; Ludewig R; Weissmann G; Abramson S
    Arthritis Rheum; 1986 Sep; 29(9):1085-9. PubMed ID: 3489467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-evaluation of the storage conditions for blood samples which are used for determination of complement activation.
    Stöve S; Klos A; Bautsch W; Köhl J
    J Immunol Methods; 1995 May; 182(1):1-5. PubMed ID: 7769237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Complement activation in patients with chronic polyarthritis, measured by the level of complement fraction C3a in plasma].
    Kapp A; Meske-Brand S; Maly FE; Müller W
    Z Rheumatol; 1984; 43(3):103-5. PubMed ID: 6332437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISAs with monoclonal antibodies.
    Klos A; Ihrig V; Messner M; Grabbe J; Bitter-Suermann D
    J Immunol Methods; 1988 Jul; 111(2):241-52. PubMed ID: 3260926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.